Syndax Pharmaceuticals (SNDX) closed at $9.45 on November 13, 2026, down 0.9% from the previous close, on volume of 2,989,694 shares (30-day average 3,376,340).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 3, 2026 | 20-Nov-26 20 P : 16-Apr-27 20 C : 16-Apr-27 20 P | 900 | |
| 2-2 | The next 1 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
Syndax Earnings Call Highlights Strong Growth and Pipeline Momentum
TipRanks (Sat, 14-Nov 9:41 PM ET)
Globe Newswire (Tue, 10-Nov 6:16 PM ET)
Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Globe Newswire (Mon, 9-Nov 5:26 PM ET)
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Globe Newswire (Wed, 4-Nov 4:01 PM ET)
Syndax spotlights ASH data with a December 14 investor event and webcast
Market Chameleon (Wed, 4-Nov 4:42 AM ET)
Syndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026
Globe Newswire (Wed, 4-Nov 9:01 AM ET)
Globe Newswire (Wed, 4-Nov 9:00 AM ET)
Syndax Announces CFO Transition - Aaron A. Ondrey Appointed Chief Financial Officer
Globe Newswire (Mon, 2-Nov 4:01 PM ET)
Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update
Globe Newswire (Mon, 2-Nov 4:01 PM ET)
Globe Newswire (Fri, 30-Oct 9:01 AM ET)
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
Syndax Pharmaceuticals trades on the NASDAQ stock market under the symbol SNDX.
As of November 13, 2026, SNDX stock price declined to $9.45 with 2,989,694 million shares trading.
SNDX has a beta of 1.46, meaning it tends to be more sensitive to market movements. SNDX has a correlation of 0.08 to the broad based SPY ETF.
SNDX has a market cap of $843.86 million. This is considered a Small Cap stock.
Last quarter Syndax Pharmaceuticals reported $83 million in Revenue and -$.55 earnings per share. This beat revenue expectation by $2 million and missed earnings estimates by -$.06.
In the last 3 years, SNDX traded as high as $25.59 and as low as $8.58.
The top ETF exchange traded funds that SNDX belongs to (by Net Assets): VTI, XBI, IWM, VXF, VTWO.
SNDX has underperformed the market in the last year with a price return of -43.3% while the SPY ETF gained +13.4%. SNDX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -50.5% and -30.8%, respectively, while the SPY returned -2.8% and -0.2%, respectively.
SNDX support price is $9.12 and resistance is $9.96 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SNDX shares will trade within this expected range on the day.
